Cargando…
Effects of a Ganoderma lucidum Proteoglycan on Type 2 Diabetic Rats and the Recovery of Rat Pancreatic Islets
[Image: see text] Type 2 diabetes (T2D) results from both insulin resistance and pancreatic β-cell dysfunction. A natural proteoglycan extracted from Ganoderma lucidum, namely, FYGL, has been demonstrated to be capable of ameliorating insulin resistance in previous work. In this work, a T2D rat mode...
Autores principales: | Yu, Fanzhen, Teng, Yilong, Li, Jiaqi, Yang, Shutong, Zhang, Zeng, He, Yanming, Yang, Hongjie, Ding, Chuan-Fan, Zhou, Ping |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2023
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10193549/ https://www.ncbi.nlm.nih.gov/pubmed/37214729 http://dx.doi.org/10.1021/acsomega.3c02200 |
Ejemplares similares
-
Interaction and Inhibition of a Ganoderma
lucidum Proteoglycan on PTP1B Activity for Anti-diabetes
por: Yu, Fanzhen, et al.
Publicado: (2021) -
Pancreatic cancer cell apoptosis is induced by a proteoglycan extracted from Ganoderma lucidum
por: Wu, Xiao, et al.
Publicado: (2021) -
Proteoglycan Extracted
from Ganoderma lucidum Ameliorated Diabetes-Induced
Muscle Atrophy via the AMPK/SIRT1 Pathway
In Vivo and In Vitro
por: Li, Jiaqi, et al.
Publicado: (2023) -
Balancing adipocyte production and lipid metabolism to treat obesity-induced diabetes with a novel proteoglycan from Ganoderma lucidum
por: Wang, YingXin, et al.
Publicado: (2023) -
Modulation of energy metabolism and mitochondrial biogenesis by a novel proteoglycan from Ganoderma lucidum
por: Yang, Zhou, et al.
Publicado: (2019)